EL USO DE CAFEÍNA EN LA TERAPIA NUTRICIONAL DE PACIENTES CON DEPRESIÓN
DOI:
https://doi.org/10.47820/recima21.v4i1.2584Palabras clave:
antidepresivo, Café, Depresión, Nootrópicos, Terapia nutricionalResumen
El café y el té son las bebidas más consumidas en el mundo, variando el patrón de consumo en la cultura de cada país. Los estudios muestran el uso de cafeína en pacientes adultos con depresión relacionada con su genética y el uso de drogas. Esta revisión tuvo como objetivo evaluar el uso de la cafeína en la terapia nutricional de pacientes con depresión, caracterizar la influencia y sus respuestas metabólicas, además de abordar estrategias nutricionales para mejorar el cuadro clínico en la depresión. Dado que el número de casos de depresión aumenta cada día, se convierte en un problema de salud pública relevante para la nutrición. Los estudios abordan que la ingestión de algunos alimentos puede contribuir reduciendo los síntomas de depresión y la protección de la función neuronal, además, los factores ambientales pueden interferir con el daño a la salud. Esta revisión abordó una bibliografía que incluía artículos científicos y tesis relacionadas con la depresión, la cafeína, las enfermedades neurológicas, el citocromo p450 y la metabolización de fármacos-nutrientes. Fueron seleccionados criterios de inclusión y exclusión, utilizando bases de datos con relevancia científica, Pubmed, Scielo, publicadas en inglés, portugués y español, a través de los descriptores: antidepresivo, café, depresión, nootrópicos y terapia nutricional. Se verificaron los efectos beneficiosos y perjudiciales del consumo de alimentos que presentan niveles de cafeína, junto con la farmacoterapia de pacientes con depresión y su influencia en la mejora cognitiva y la neuroprotección, la prevención de enfermedades neurodegenerativas y el bienestar de estos individuos.
Descargas
Referencias
Chang D, Song D, Zhang J, Shang Y, Ge Q, Wang Z. Caffeine Caused a Widespread Increase of Resting Brain Entropy. Scientific Reports. 2018; 8(1).
Santos C, Costa J, Santos J, Vaz-Carneiro A, Lunet N. Caffeine intake and dementia: a systematic review and meta-analysis. Journal of Alzheimer's Disease:JAD. 2010; 20 (Supplement 1):S187-204.
Ding M, Bhupathiraju SN, Satija A, Van Dam RM, Hu FB. Long-term coffee consumption and cardiovascular disease risk: a systematic review and a doseresponse meta-analysis of prospective cohort studies. Circulation. 2014; 129:643-59.
Ding M, Bhupathiraju SN, Chen M, van Dam RM, Hu FB. Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: a systematic review and a dose-response meta-analysis. Diabetes care. 2014; 37:569-586.
Ross GW, et al. Association of coffee and caffeine intake with risk of Parkinson's disease. never. 2000; 283:2674-2679.
Freedman ND, Park Y, Abnet CC, Hollenbeck AR, Sinha R. Association of coffee consumption with total and cause-specific mortality. The New English Journal of medicine. 2012; 366:1891-1904.
Ding M, et al. Association of coffee consumption with total and cause-specific mortality in 3 large prospective cohorts. Circulation. 2015; 132:2305–2315.
Loftfield E, et al. Association of coffee consumption with general and cause-specific mortality in a large prospective cohort study in the USA. American Journal of Epidemiology. 2015; 182:1010–1022.
Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H. Coffee, CYP1A2 genotype and risk of myocardial infarction. never. 2006; 295:1135-1141.
Feng L, Gwee X, Kua EH, Ng TP. Cognitive function and tea consumption in the Chinese elderly community in Singapore. Journal of Nutrition, Health and Aging. 2010; 14:433-438.
Araújo LF, et al. Association of coffee consumption with MRI markers and cognitive function: a population-based study. Journal of Alzheimer's Disease: JAD. 2016; 53:451-461.
Araújo LF, Giatti L, Reis RC, Goulart AC, Schmidt MI, Duncan BB, Ikram MA, Barreto SM. Inconsistency of Association between Coffee Consumption and Cognitive Function in Adults and Elderly in a Cross-Sectional Study (ELSA-Brasil). Nutrients. 2015 Nov 19;7(11):9590-601
McMahon G, Taylor AE, Davey Smith G, Munafò MR (2014) Phenotype Refinement Strengthens the Association of AHR and CYP1A1 Genotype with Caffeine Consumption. PLoS ONE 9(7): e103448.
Josse AR, Da Costa LA, Campos H, El-Sohemy A. Associations between polymorphisms in the AHR and CYP1A1-CYP1A2 gene regions and habitual caffeine consumption. The American Journal of Clinical Nutrition. 2012; 96:665-671.
Cornelis MC, et al. The genome-wide association study of caffeine metabolites provides new insights into caffeine metabolism and dietary caffeine consumption behavior. Human molecular genetics. 2016; 25:5472-5482.
Grosso G, Micek A, Castellano S, Pajak A, Galvano F. Coffee, tea, caffeine and risk of depression: A systematic review and dose-response meta-analysis of observational studies. Mol Nutr Food Res. 2016 Jan; 60(1):223-34.
Guengerich FP, Waterman MR, Egli M. Recent structural insights into cytochrome P450 function. Trends Pharmacol Sci 2016; 7(8):625-40.
Chuang, Yu-Hsuan, et al. "Gene-environment interaction in Parkinson's disease: coffee, ADORA2A, and CYP1A2." Neuroepidemiology 47.3-4 (2016): 192-200.
Hill-Burns, Erin M., et al. "An attempt to replicate interaction between coffee and CYP1A2 gene in connection to Parkinson’s disease." European journal of neurology: the official journal of the European Federation of Neurological Societies 18.9 (2011): 107.
Jee HJ, Lee SG, Bormate KJ, Jung YS. Effect of Caffeine Consumption on the Risk for Neurological and Psychiatric Disorders: Sex Differences in Human. Nutrients. 2020 Oct 9;12(10):3080.
Strafella C, Caputo V, Galota MR, Zampatti S, Marella G, Mauriello S, et al. Aplicação da Medicina de Precisão em Doenças Neurodegenerativas. Frente. Neural. 2018; 9:701.
Scalabrino G. Vitamin-regulated cytokines and growth factors in the CNS and elsewhere. J Neurochem. 2009 Dec;111(6):1309-26.
MOURA, Ribeiro M, Felix G. Interação fármaco-nutriente: uma revisão. Revista de Nutrição. 2002, v. 15, n. 2 Acessado 3 dezembro 2022, pp. 223-238.
Patel M, Taskar KS, Zamek- Gliszczynski MJ. Importance of hepatic transporters in clinical disposition of drugs and their metabolites. J Clin Pharmacol 56(Suppl 7):S23–S39, 2016.
Ortega MA, Fraile-Martínez Ó, García-Montero C, Alvarez-Mon MA, Lahera G, Monserrat J, et al. Biological Role of Nutrients, Food and Dietary Patterns in the Prevention and Clinical Management of Major Depressive Disorder. Nutrients. 2022 Jul 28;14(15):3099.
MAHAN LK, ESCOTT-STUMP, S RAYMOND, J.L Krause: Alimentos, Nutrição e Dietoterapia. 13ª ed. Rio de Janeiro: Elsevier, 2013. 1228 p.
Tavares, Cristiane e Sakata, Rioko K. Cafeína para o tratamento de dor. Revista Brasileira de Anestesiologia. 2012 v. 62, n. 3 pp. 394-401.
CAMPOS C. Alimentos com cafeína. In: STEIN, Kelly. 2011. Disponível em: Acesso 01 mai. 2017CAMPOS, apud STEIN, 2011
Vasconcelos S, Silva M, Goulart M. Pró-antioxidantes de baixo peso molecular oriundos da dieta: estrutura e função. 2006: 31(3) 95-118
Perera V, Gross AS, Xu H, McLachlan AJ. Farmacocinética da cafeína no plasma e na saliva e a influência da abstinência de cafeína nas métricas do CYP1A2. J Pharm Pharmacol. 2011;63(9):1161-8.
Malik R, Sangwan A, Saihgal R, Jindal DP, Piplani P. Towards better brain management: nootropics. Curr Med Chem. 2007;14(2):123-31.
Malík M, Tlustoš P. Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs. 2022;14(16):3367.
Oliveira I, Belenichev I, Demchenko A, Bobrova V, Kucherenko L, Gorchakova N, et al. Nootrópicos na terapia comlex de isquemia cerebral crônica. pp. 56–68.
Nicholson CD. Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. 101, 147–159 (1990).
Cavalcanti V, Marques M, Rocha A, Ferreira IDJ, Leão DP, et al. Bioproducts based on guarana (Paulinia cupana) for practitioners of physical activity. 2020: 8, 1746–1759.
Kennedy D, Haskell C, Wesnes K, Scholey A. Improved cognitive performance in human volunteers following administration of guarana (Paullinia cupana) extract: Comparison and interaction with Panax ginseng. Pharmacol. Biochem. Behav. 2004: 79, 401–411.
Wikoff D, Welsh BT, Henderson R, Brorby GP, Britt J, Myers E. Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. Food Chem Toxicol. 2017 Nov;109: 585-648.
Echeverri, Darío, et al. "Caffeine's vascular mechanisms of action." International journal of vascular medicine 2010 (2010).
Brunton, Laurence L. et al. Goodman & Gilman: As bases farmacológicas da terapêutica. 11a Edição. Porto Alegre (RS): Mc Graw Hill/Artmed, 2010.
Kolahdouzan M, Hamadeh M. The neuroprotective effects of caffeine in neurodegenerative diseases. CNS Neurosci Ther. 2017 Apr:23(4):272-290.
Kim I, O'Reilly E, Hughes K, Gao X, Schwarzschild M, McCullough M, et al. Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk. Mov Disord. 2018: 33(3):414-420
Siokas V, Aloizou A, Tsouris Z, et al. ADORA2A rs5760423 and CYP1A2 rs762551 Polymorphisms as Risk Factors for Parkinson's Disease. J Clin Med. 2021:10(3):381. Published 2021
Popat R, Van Den Eeden S, Tanner C, Kamel F, Umbach D, Marder K, et al (2011), Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson’s disease. European Journal of Neurology, 18: 756-765.
Wang L, Shen X, Wu Y, Zhang D. Coffee and caffeine consumption and depression: A meta-analysis of observational studies. Australian & New Zealand Journal of Psychiatry. 2016;50(3):228-242.
Kim J, Kim J. Green Tea, Coffee, and Caffeine Consumption Are Inversely Associated with Self-Report Lifetime Depression in the Korean Population. Nutrients. 2018: 10(9):1201.
Lucas, Michel, et al. "Coffee, caffeine, and risk of depression among women." Archives of internal medicine 171.17 (2011): 1571-1578.
Perera V, Gross AS, Xu H, McLachlan AJ. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. J Pharm Pharmacol. 2011 Se:63(9):1161-
Kashuba A, Nafziger A, Kearns G, Leeder J, Gotschall R, Rocci M. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther. 1998 Sep 64(3):257-68
Descargas
Publicado
Número
Sección
Categorías
Licencia
Derechos de autor 2023 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
